The Modified "Pills-in-the-Pocket" Strategy -The Combined Effect of Amiodarone, Bisoprolol and Digoxin in the Treatment of Recurrent Atrial Arrhythmia for Non-Paroxysmal Atrial Fibrillation After Catheter Ablation: A Multicenter, Prospective, Randomized, Open-Label, Blinded Endpoint Clinical Trial

This is a multicentre, prospective, randomised controlled study of 328 patients with non-paroxysmal AF (within 5 years of first diagnosis of AF) with recurrent atrial arrhythmias after first catheter ablation, randomly divided in a 1:1 ratio into a study group treated with triple AADs (amiodarone + bisoprolol + digoxin) and a control group treated with conventional AADs (amiodarone + bisoprolol + digoxin). The study group was treated with triple AADs (amiodarone + bisoprolol) and the control group was treated with conventional AADs (amiodarone + bisoprolol) with the aim of comparing the efficacy and safety of the two groups in terms of reversion of SR, which may provide an effective option of pocket drug reversion for patients with recurrence of SR after AF catheter ablation.
Translated with DeepL.com (free version)

Start Date23 Oct 2024

Sponsor / Collaborator

Guangdong General Hospital

[+6]

NCT06603207 / Not yet recruitingNot ApplicableIIT

Causal Association Between Rheumatoid Arthritis and Periodontitis: A Mendelian Randomization Study

This study aims to investigate the causal relationship between rheumatoid arthritis and periodontitis using Mendelian randomization. Data will be sourced from genome-wide association studies (GWAS) to explore genetic associations and assess potential risk factors in an East Asian population.

Start Date01 Oct 2024

Sponsor / Collaborator

Guangzhou Institute of Respiratory Disease

[+1]

NCT06445088 / RecruitingNot ApplicableIIT

Evaluation of Diagnostic Performance of a Detection Kit for Epstein-Barr Virus C Promoter Methylation in Nasopharyngeal Carcinoma

This clinical study aims to evaluate the diagnostic performance of a new Epstein-Barr virus (EBV) C promoter methylation detection kit. All participants will undergo a series of diagnostic tests including VCA-IgA, EBNA1-IgA, and EBV-DNA assays. Additionally, nasopharyngeal swabs will be analyzed for EBV C promoter methylation. Confirmatory biopsy will be performed on all patients to establish a definitive diagnosis. This comprehensive approach seeks to assess the effectiveness of the methylation detection kit in a clinical setting.

Start Date29 May 2024

Sponsor / Collaborator

Sun Yat-Sen University

[+3]

100 Clinical Results associated with Zhongshan People's Hospital

0 Patents (Medical) associated with Zhongshan People's Hospital

499

Literatures (Medical) associated with Zhongshan People's Hospital

01 Dec 2024·Current Molecular Medicine

Preparation of Menthyl 3-amino-4-(2,4,5-trifluorophenyl) Butyrate and Investigation of its Hypoglycemic Activity

Article

Author: Li, Hao ; Xie, Shuilin ; Su, Minru ; Cai, Huan ; Kuang, Xinmou ; Sheng, Xiaolan ; Liu, Zhonghua

Background:3-Amino-4-(2,4,5-trifluorophenyl) butyric acid has potential pharmacological effects in promoting insulin secretion. Menthol promotes drug transdermal absorption and hypoglycemic effects.Objective:The objective of the study was to combine the 3-amino-4-(2,4,5- trifluorophenyl) butyric acid and menthol to develop a new candidate drug molecule that can be used as a hypoglycemic drug in type II diabetes.Methods:In this study, the molecular structure of 3-amino-4-(2,4,5-trifluorophenyl) butyric acid in sitagliptin was modified by replacing pyrazine imidazole with menthol. The structure of the target compound was characterized by nuclear magnetic resonance (NMR). The anti-diabetic activity of BHF in N000180 BKS.Cg-Dock7m+/ +Leprdb/Nju mice with spontaneous diabetes was preliminarily studied.Results:A potential multi-target drug molecule, 3-amino-4-(2,4,5-trifluorophenyl) butyrate (BHF), was synthesized by combining 3-amino-4-(2,4,5-trifluorophenyl) butyric acid and menthol. BHF is suitable for hyperglycemic mice and has a significant hypoglycemic effect; the low dose of 10 mg/kg-1 started to be effective, and the high dose of 40 mg/kg-1 was more effective than the positive drug metformin.Conclusion:In this study, BHF has been synthesized and presented significant antidiabetic activities.

01 Oct 2024·American Journal of Transplantation

Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study

Article

Author: Hu, Zemin ; Zhu, Zhijun ; Wang, Wenjing ; Wang, Mengchao ; Ling, Qi ; Jia, Zehua ; Liu, Yao ; Liu, Chao ; Guo, Zhiyong ; Li, Ling ; Wang, Tielong ; Sun, Qiang ; Zeng, Ping ; Yu, Sheng ; Zhang, Fan ; Zhang, Shuhua ; Wang, Shaoping ; Chen, Huanwei ; Zheng, Shusen ; Luo, Qijie ; Zheng, Zhouying ; Jia, Yingbin ; Schlegel, Andrea ; Li, Chuanjiang ; Nashan, Björn ; Deng, Feiwen ; Wang, Yanfeng ; Liang, Wenjin ; Xu, Leibo ; Liu, Ying ; Li, Jian ; He, Xiaoshun ; Xiong, Jun ; Han, Zemin ; Lin, Yimou ; Zhu, Jiaxing ; Qu, Wei ; Zheng, Yujian ; Zhang, Jian ; Lu, Xinjun

Immune checkpoint inhibitors (ICIs) as a downstaging or bridging therapy for liver transplantation (LT) in hepatocellular carcinoma patients are rapidly increasing. However, the evidence about the feasibility and safety of pre-LT ICI therapy is limited and controversial. To this end, a multicenter, retrospective cohort study was conducted in 11 Chinese centers. The results showed that 83 recipients received pre-LT ICI therapy during the study period. The median post-LT follow-up was 8.1 (interquartile range 3.3-14.6) months. During the short follow-up, 23 (27.7%) recipients developed allograft rejection, and 7 of them (30.4%) were diagnosed by liver biopsy. Multivariate logistics regression analysis showed that the time interval between the last administration of ICI therapy and LT (TLAT) ≥ 30 days was an independent protective factor for allograft rejection (odds ratio = 0.096, 95% confidence interval 0.026-0.357; P < .001). Multivariate Cox analysis showed that allograft rejection was an independent risk factor for overall survival (hazard ratio = 9.960, 95% confidence interval 1.006-98.610; P = .043). We conclude that patients who receive a pre-LT ICI therapy with a TLAT shorter than 30 days have a much higher risk of allograft rejection than those with a TLAT longer than 30 days. The presence of rejection episodes might be associated with higher post-LT mortality.

01 Sep 2024·Neurology Neuroimmunology & Neuroinflammation

Single-Cell RNA Sequencing Reveals Transcriptional Landscape of Neutrophils and Highlights the Role of TREM-1 in EAE

Article

Author: Cui, Xiaoyang ; Yi, Le ; Ba, Yongbing ; Quan, Moyuan ; Bi, Yanwei ; Zhang, Huining ; Li, Bin ; Han, Xianxian

BACKGROUND AND OBJECTIVESNeutrophils, underestimated in multiple sclerosis (MS), are gaining increased attention for their significant functions in patients with MS and the experimental autoimmune encephalomyelitis (EAE) animal model. However, the precise role of neutrophils in cervical lymph nodes (CLNs), the primary CNS-draining lymph nodes where the autoimmune response is initiated during the progression of EAE, remains poorly understood.METHODSApplying single-cell RNA sequencing (scRNA-seq), we constructed a comprehensive immune cell atlas of CLNs during development of EAE. Through this atlas, we concentrated on and uncovered the transcriptional landscape, phenotypic and functional heterogeneity of neutrophils, and their crosstalk with immune cells within CLNs in the neuroinflammatory processes in EAE.RESULTSNotably, we observed a substantial increase in the neutrophil population in EAE mice, with a particular emphasis on the significant rise within the CLNs. Neutrophils in CLNs were categorized into 3 subtypes, and we explored the specific roles and developmental trajectories of each distinct neutrophil subtype. Neutrophils were found to engage in extensive interactions with other immune cells, playing crucial roles in T-cell activation. Moreover, our findings highlighted the strong migratory ability of neutrophils to CLNs, partly regulated by triggering the receptor expressed on myeloid cells 1 (TREM-1). Inhibiting TREM1 with LR12 prevents neutrophil migration both in vivo and in vitro. In addition, in patients with MS, we confirmed an increase in peripheral neutrophils with an upregulation of TREM-1.DISCUSSIONOur research provides a comprehensive and precise single-cell atlas of CLNs in EAE, highlighting the role of neutrophils in regulating the periphery immune response. In addition, TREM-1 emerged as an essential regulator of neutrophil migration to CLNs, holding promise as a potential therapeutic target in MS.

100 Deals associated with Zhongshan People's Hospital

100 Translational Medicine associated with Zhongshan People's Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 26 Dec 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Zhongshan People's Hospital

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 26 Dec 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing